ACCD:NSD-Accolade, Inc (USD)

COMMON STOCK | Health Information Services | NSD

Last Closing Price

USD 39.92

Change

0.00 (0.00)%

Market Cap

USD 2.32B

Volume

1.69M

Average Target Price

USD 53.13 (+33.08%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Accolade, Inc. develops and provides technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and with multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. Its customers are primarily employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania. Address: 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-07 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CERN Cerner Corporation

N/A

USD21.56B 27.93 12.63
TXG 10x Genomics, Inc

N/A

USD16.92B N/A N/A
GDRX GoodRx Holdings, Inc

N/A

USD16.17B 927.27 243.40
CHNG Change Healthcare Inc

N/A

USD6.83B N/A N/A
HQY HealthEquity, Inc

N/A

USD6.59B 1,765.78 47.41
RCM R1 RCM Inc

N/A

USD6.58B 77.13 37.57
OMCL Omnicell, Inc

N/A

USD5.35B 168.07 50.71
CVET Covetrus, Inc

N/A

USD4.27B 40.87 24.10
PINC Premier, Inc

N/A

USD4.13B 13.28 9.91
INOV Inovalon Holdings, Inc

N/A

USD3.95B 174.38 25.32

ETFs Containing ACCD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.23% 10% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.23% 10% F 16% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.32B 59% F 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 99% A+
Price/Book Ratio 6.31 33% F 30% F
Price / Cash Flow Ratio -67.77 83% B 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -26.90% 30% F 32% F
Return on Invested Capital 59.35% 100% A+ 98% A+
Return on Assets -9.94% 18% F 28% F
Debt to Equity Ratio -304.17% 100% A+ 97% A+
Technical Ratios  
Short Ratio 2.48 72% C- 47% F
Short Percent 7.24% 41% F 27% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.